PULSED DURATION EFFECT ON LASER - VASCULAR DISEASE THERAPY

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1988
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
8068
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Phase-r Corp
Box G-2 Old Bay Rd, New Durham, NH, 03855
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
() -
Business Contact:
() -
Research Institution:
n/a
Abstract
THE TREATMENT OF CUTANEOUS BLOOD VESSEL DISEASE PROCESSES HAS PRODUCED INCONSISTENT RESULTS. LESIONS SUCH AS PORTWINESTAINS AND TELANGIECTASIA HAVE RESPONDED OCCASIONALLY WITH RESOLUTION OF THE LESION BUT OFTEN DO NOT RESPOND OR DEVELOPSERIOUS ADVERSE SIDE EFFECTS. THE ARGON LASER, WHICH HAS MADE THE GREATEST GAINS IN TREATING THESE LESIONS, CAN STILLPRODUCE SERIOUS SCARRING, SKIN TEXTURE CHANGES OR ADVERSE DISCOLORATION. THE PULSED DYE LASER HAS REDUCED THESE RISKS BUT IS UNABLE TO AFFORD THE PATIENT OPTIMAL RESULTS WITH CURRENT DESIGN CONSTRAINTS, PRINCIPALLY A SHORT 360 USED PULSE DURATION. LARGER DIAMETER AND DEEP SEATED VESSELS WILL NOT RESOLVE. A PULSED DYE LASER WITH MILLISECOND RANGE PULSE DURATION CAPABILITIES WILL BE DEVELOPED AND CLINICALLY EVALUATED FOR THE CUTANUEOUS LASER-TISSUE INTERACTION IN BOTH NORMAL AND LESIONAL SKIN. IT IS ANTICIPATED THE LONGER PULSE DURATION WILL ALLOW BETTER LESIONAL RESOLUTION WHILE MAINTAINING MINIMAL PATIENT RISK. RESULTS FROM THE PHASE-I STUDIES WILL DIRECT FUTURE LASER DEVELOPMENT TOWARD OPTIMIZING CLINICAL OUTCOME.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government